Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Kim on Efficacy and Next Steps With Regorafenib/Nivolumab Combo in CRC

July 3rd 2020

Richard D. Kim, MD, discusses the efficacy of and next steps for a phase 1/1b study with regorafenib and nivolumab in patients with mismatch repair proficient advanced refractory colorectal cancer.

Dr. Lenz on Updated Data From CheckMate 142 With Nivolumab + Ipilimumab in mCRC

July 2nd 2020

Heinz-Josef Lenz, MD, FACP, discusses updated efficacy data from the phase 2 CheckMate-142 trial with nivolumab plus low-dose ipilimumab in metastatic colorectal cancer.

Dr. Fakih on the Safety Profile of AMG 510 in KRAS G12C-Mutated CRC

July 2nd 2020

Marwan Fakih, MD, discusses the safety profile of AMG 510 in KRAS G12C-mutated colorectal cancer.

Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC

June 29th 2020

Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.

FDA Approves First-Line Pembrolizumab for MSI-H/dMMR Metastatic Colorectal Cancer

June 29th 2020

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Future Directions in Later Line Therapy for mCRC

June 29th 2020

Key Trials in mCRC: I/O Combination Therapies

June 29th 2020

Role of I/O Combination Therapies in mCRC

June 29th 2020

Using I/O in MSI-H Tumors in mCRC

June 29th 2020

Sequencing in mCRC: Later-Line Therapies

June 29th 2020

Therapeutic Agents in Relapsed/Refractory mCRC

June 29th 2020

CORRECT, RECOURSE, and ReDOS Trials in mCRC

June 29th 2020

Later Lines of Therapy for mCRC

June 29th 2020

Second-Line Treatment for mCRC

June 29th 2020

Initiating Therapy for mCRC

June 29th 2020

Continuum of Care for Metastatic CRC

June 29th 2020

Dr. Wang on Challenges With Checkpoint Inhibitors in CRC

June 23rd 2020

Timothy Cragin Wang, MD, discusses the lack of response to checkpoint inhibitors in colorectal cancer.

Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC

June 23rd 2020

Scott Kopetz, MD, PhD, FACP, discusses the safety data reported from the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

FDA Grants Fruquintinib Fast Track Status for mCRC

June 18th 2020

The FDA has granted a fast track designation to fruquintinib for the treatment of patients with metastatic colorectal cancer who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, VEGF-directed therapy, and EGFR-directed therapy.

Siena Showcases Trastuzumab Deruxtecan Activity in HER2-Expressing mCRC

June 9th 2020

Salvatore Siena, MD, further discusses the DESTINY-CRC01 trial with trastuzumab deruxtecan and projects the impact of these findings on patients with HER2-expressing metastatic CRC.